Advertisement

Digestive Diseases and Sciences

, Volume 52, Issue 9, pp 2044–2053 | Cite as

Leukocytapheresis (LCAP) in the Management of Chronic Active Ulcerative Colitis—Results of a Randomized Pilot Trial

  • Jörg Emmrich
  • Sebastian Petermann
  • Dietrich Nowak
  • Ingolf Beutner
  • Peter Brock
  • Reinhard Klingel
  • Patrick Mausfeld-Lafdhiya
  • Stefan Liebe
  • Wolfgang Ramlow
ORIGINAL ARTICLE

Abstract

Recent studies suggest that leukocytapheresis with Cellsorba is a valuable therapy for ulcerative colitis after failure of conventional treatment. In this study the potential of leukocytapheresis to induce remission in refractory chronic colitis under the conditions of European treatment guidelines was investigated. The therapeutic benefit of leukocytapheresis in the maintenance of remission was additionally elucidated. Twenty patients were treated weekly for 5 weeks. A significant decrease in the activity index was observed. Fourteen patients achieved clinical remission, and mucosal healing was observed endoscopically in six patients. After randomization these 14 patients in remission entered a second period of either monthly leukocytapheresis or no further treatment. In both groups steroids were tapered down. After 6 months, only one patient in the control group remained in remission, in contrast to five of eight patients in the leukocytapheresis group. In conclusion, leukocytapheresis may offer a therapeutic option in the induction and the maintenance of remission in chronic active ulcerative colitis.

Keywords

Leukocytapheresis Inflammatory bowel disease Ulcerative colitis Immunosuppression 

Notes

Acknowledgments

The authors wish to thank the apheresis nurses at the Centre for Apheresis, Rostock, for all their efforts and technical assistance during the performace of LCAP treatments. This work was sponsored by Asahi Medical Co., Ltd. (9-1, Kanda Mitoshirocho, Chiyoda-ku, Tokyo 101-8482, Japan), and Asahi Medical GmbH (Arabella Center, Lyoner Str. 44-48, 60528 Frankfurt am Main, Germany).

References

  1. 1.
    Bouma G, Strober W (2003) The immunological and genetic basis of inflammatory bowel disease. Nature Rev Immunol 3:521–533CrossRefGoogle Scholar
  2. 2.
    Sandborn WJ (1998) Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol 225:92–99CrossRefGoogle Scholar
  3. 3.
    Hanauer SB (2004) Medical therapy for ulcerative colitis 2004. Gastroenterol 126:1582–1592CrossRefGoogle Scholar
  4. 4.
    Baumgart DC, Wiedenmann B, Dignass AU (2003) Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 17:1273–1281PubMedCrossRefGoogle Scholar
  5. 5.
    Loftus CG, Loftus EV, Sandborn WJ (2003) Cyclosporin for refractory ulcerative colitis. Gut 52:172–173PubMedCrossRefGoogle Scholar
  6. 6.
    Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417–429PubMedCrossRefGoogle Scholar
  7. 7.
    Blumberg RS, Saubermann LJ, Strober W (1999) Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 11:648–656PubMedCrossRefGoogle Scholar
  8. 8.
    Neurath MF, Finotto S, Glimcher LH (2002) The role of Th1/Th2 polarization in mucosal immunity. Nature Med 8:567–573PubMedCrossRefGoogle Scholar
  9. 9.
    Shibata H, Kuriyama T, Yamawaki N (2003) Cellsorba. Ther Apher Dial 7:44–47PubMedCrossRefGoogle Scholar
  10. 10.
    Kohgo Y, Ashida T, Maemoto A, Ayabe T (2003) Leukocytapheresis for treatment of IBD. J Gastroenterol 38 (Suppl 15):51–54PubMedGoogle Scholar
  11. 11.
    Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, Hiwatashi N, Asakura H, Hibi T (2003) Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 9:307–321PubMedCrossRefGoogle Scholar
  12. 12.
    Sawada K, Ohnishi K, Kosaka T, Chikano S, Yokota Y, Egashira A, Izawa H, Yamamura M, Amano K, Satomi M, Shimoyama T (1997) Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apher 1:207–211PubMedGoogle Scholar
  13. 13.
    Ueki Y, Yamasaki S, Kanamoto Y, Kawazu T, Yano M, Matsumoto K, Miyake S, Tominaga Y, Iwamoto U, Suemitsu J, Matsuno Y, Sizume Y, Takenaka Y, Eguchi K (2000) Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis. Rheumatol 39:165–171CrossRefGoogle Scholar
  14. 14.
    Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Kataharada K, Ishizuka T, Kawakami M, Nakamura H (1999) Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double blind, placebo-controlled trial. Arth Rheum 42:431–437CrossRefGoogle Scholar
  15. 15.
    Hidaka T, Suzuki K, Kawakami M, Okada M, Kataharada K, Shinohara T, Takamizawa-Matsumoto M, Ohsuzu F (2001) Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J Clin Apher 16:74–81PubMedCrossRefGoogle Scholar
  16. 16.
    Hidaka T, Suzuki K (2003) Leukocytapheresis for rheumatic disease. Ther Apher 7:161–166CrossRefGoogle Scholar
  17. 17.
    Kempe K, Tsuda H, Yang K, Yamaji K, Kanai Y, Hashimoto H (2004) Filtration leukocytapheresis therapy in the treatment of rheumatoid arthritis patients resistant to or failed with methotraxate. Ther Apher Dial 197–205Google Scholar
  18. 18.
    Sawada K, Ohnishi K, Kosaka T, Chikano S, Egashira A, Okui M, Shintani S, Wada M, Nakasho K, Shimoyama T (1997) Exacerbated autoimmune hepatitis successfully treated with leukocytapheresis and bilirubin adsorption therapy. J Gastroenterol 32:689–695PubMedCrossRefGoogle Scholar
  19. 19.
    Kosaka T, Sawada K, Ohnishi K, Egashira A, Yamamura M, Tanida N, Satomi M, Shimoyama T (1999) Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn’s disease. Intern Med 38:102–111PubMedGoogle Scholar
  20. 20.
    Rachmilewitz D, et al. (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized study. BMJ 298:82–86PubMedCrossRefGoogle Scholar
  21. 21.
    Sawada K, Ohnishi K, Kosaka T, Fukui S, Yamamura M, Amano K, Satomi M, Shimoyama T (1995) Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease. J Gastroenterol 30 (Suppl 8):124–127PubMedGoogle Scholar
  22. 22.
    Amano K, Amano K (1998) Filter leukocytapheresis for patients with ulcerative colitis: clinical results and the possible mechanism. Ther Apher 2:97–100PubMedGoogle Scholar
  23. 23.
    Irving PM, Rampton DS (2004) Leucocytapheresis for ulcerative colitis. Dig Liver Dis 36:799–802PubMedCrossRefGoogle Scholar
  24. 24.
    Noguchi M, Hiwatishi N, Hayakawa T, Toyota T (1998) Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Ther Apher 2:109–114PubMedGoogle Scholar
  25. 25.
    Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C (2003) Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 52:1435–1441PubMedCrossRefGoogle Scholar
  26. 26.
    Danese S, Motte C de la, Fiocchi C (2004) Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 99:938–945PubMedCrossRefGoogle Scholar
  27. 27.
    Neurath MF, Finotto S, Fuss I, Boirivant M, Galle PR, Strober W (2001) Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trend Immunol 22:21–26CrossRefGoogle Scholar
  28. 28.
    Rosen H, Sanna G, Alfonso C (2003) Egress: a receptor-regulated step in lymphocyte trafficking. Immunol Rev 195:160– 177PubMedCrossRefGoogle Scholar
  29. 29.
    Nagase K, Sawada K, Ohnishi K, Egashira A, Ohkusu K, Shimoyama T (1998) Complications of leukocytapheresis. Ther Apher 2:120–124PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Jörg Emmrich
    • 1
  • Sebastian Petermann
    • 2
  • Dietrich Nowak
    • 2
  • Ingolf Beutner
    • 2
  • Peter Brock
    • 2
  • Reinhard Klingel
    • 3
    • 4
  • Patrick Mausfeld-Lafdhiya
    • 5
  • Stefan Liebe
    • 2
  • Wolfgang Ramlow
    • 6
  1. 1.Division of Gastroenterology, Department of Internal MedicineUniversity Hospital of RostockRostockGermany
  2. 2.Department of Internal MedicineUniversity Hospital of RostockRostockGermany
  3. 3.Apheresis Research InstituteCologneGermany
  4. 4.Apheresis Research InstituteTorontoCanada
  5. 5.Apheresis Research InstituteCologneGermany
  6. 6.Center for ApheresisRostockGermany

Personalised recommendations